

1/21



Figure 1 A

2/21




Figure 1B

[illegible]

Figure 1C

SUBSTITUTE SHEET (RULE 26)




Figure 2A




Figure 2B




Figure 3




Figure 4

8/21




Figure 5A

9/21

B

Helicity percentage



C

RMS fluctuations




Figure 5B & C

10/21




Figure 6

11/21




Figure 7

12/21




Figure 8

13/21

**Intramuscular immunisation (x3) with p*17-DT+K4S2-DT/Alum and
Intranasal challenge with 5448AP (CovR/S MT strain)**

Immunisation groups

- A. p*17-DT/Alum – total 25 µg
- B. p*17-DT+K4S2-DT/Alum – 12.5 µg p*17-DT and 12.5 µg K4S2-DT
- C. PBS/Alum

Immunisation schedule – Intramuscular

Day 0 → Day 21 → Day 42 → Day 50 → Day 60

i.m.	i.m.	i.m.	Serum	Intranasal
			Saliva	Challenge
				5448AP

Figure 9




Figure 10




Figure 11

16/21




Figure 12




Figure 13




Figure 14

19/21




Figure 15

20/21




Figure 16A

21/21




Figure 16B